乐普（北京）医疗器械股份有限公司 证券代码：300003 证券简称：乐普医疗 公告编号：2025-014 乐普（北京）医疗器械股份有限公司2024年年度报告全文及报告摘要于2025 年 4 月 19 日 在 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露，敬请投资者注意查阅。 特此公告。 2024 年年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 乐普（北京）医疗器械股份有限公司 董事会 二○二五年四月十九日 ...

董事会 二〇二五年四月十九日 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 等要求，乐普（北京）医疗器械股份有限公司（以下简称"公司"）董事会就公 司在任独立董事的独立性情况进行评估并出具如下专项意见： 经核查，公司独立董事甘亮先生、王立华先生、曲新女士未在公司担任除独 立董事以外的任何职务，也未在公司主要股东公司担任任何职务，与公司及主要 股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系，不存在其 他影响独立董事独立性的情况，因此，公司独立董事符合《上市公司独立董事管 理办法》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》等法律法规及《公司章程》中对独立董事的任职资格及独立性的相关要 求。 乐普（北京）医疗器械股份有限公司 乐普（北京）医疗器械股份有限公司 董事会关于独立董事独立性情况的专项意见 ...

关于乐普（北京）医疗器械股份有限公司2024年度募集资 金存放与使用情况 专项报告的鉴证报告 关于乐普（北京）医疗器械股份有限公司 2024 年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第 ZG11562 号 乐普（北京）医疗器械股份有限公司 募集资金存放与使用情况 鉴证报告 | 目 | 录 | 页 | 次 | | --- | --- | --- | --- | | 一、募集资金年度存放与使用情况鉴证报告 | 1-3 | | | | 二、2024 | 年度募集资金存放与实际使用情况的专项报告 | 4-11 | | | 三、附表一：募集资金使用情况对照表 | 12-13 | | | | 附表二：境外公开发行GDR项目募集资金使用情况对照表 | 14 | | | 信会师报字[2025]第ZG11562号 乐普（北京）医疗器械股份有限公司全体股东： 我们接受委托，对后附的乐普（北京）医疗器械股份有限公司（以 下简称"乐普医疗"）2024年度募集资金存放与使用情况专项报告（以 下简称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 乐普医疗公司董事会的责任是按照中国证券监督 ...

乐普（北京）医疗器械股份有限公司 2024 年度财务决算报告 证券代码：300003 证券简称：乐普医疗 公告编号：2025-013 乐普（北京）医疗器械股份有限公司 2024 年度财务决算报告 2025 年 4 月 乐普（北京）医疗器械股份有限公司 2024 年度财务决算报告 报告期末，公司按照《企业会计准则》及《深圳证券交易所股票上市规则》的相关 要求对 2024 年度存在减值迹象的资产以及对所有投资形成的商誉进行系统性减值测 试，并聘请独立的专业评估机构针对特定公司进行评估，绝大部分企业，特别是几个 大型企业经营状况良好，无计提减值的风险。基于公司的审慎评估，商誉和其他特定 资产共发生减值损失合计 25,128.08 万元，其对归属于上市公司股东的净利润的影响 为 21,666.94 万元。主要包括：收购苏州博思美形成的商誉净额为 8,910.17 万元，计 提减值准备 5,928.22 万元，收购乐普装备形成的商誉为 934.28 万元，计提减值准备 366.56 万元；公司的应急产品存货经过审慎评估，计提减值准备 13,575.09 万元；公 司自研的新冠 POCT 无形资产计提减值准备 1,578 ...

Core Viewpoint - The percutaneous coronary intervention (PCI) market in China is experiencing significant growth due to increasing rates of cardiovascular diseases driven by aging population and rising obesity rates, with the number of PCI procedures expected to reach 3.6 million by 2030 from 1.9 million in 2024 [1][11]. Industry Overview - PCI is a minimally invasive procedure aimed at improving blood flow in narrowed or blocked coronary arteries, with various techniques including balloon angioplasty and stent implantation [1][5]. - The PCI industry is supported by a supply chain that includes raw materials like stainless steel and cobalt-chromium alloys, as well as advanced medical devices and technologies [5]. Industry Environment - China has approximately 330 million patients with cardiovascular diseases (CVD), with a significant portion being elderly, which correlates with a rising incidence of heart diseases [7]. - The aging population in China is projected to increase from 145 million in 2015 to 220 million by the end of 2024, leading to a higher prevalence of cardiovascular diseases [7]. Industry Status - The total number of registered PCI cases in China reached 1,636,055 in 2023, marking a year-on-year growth rate of 26.44%, the highest recorded [9]. - National policies are enhancing healthcare services and infrastructure, leading to increased accessibility and acceptance of PCI procedures among patients [11]. Development Trends - The PCI industry is witnessing rapid technological innovation and product upgrades, with advancements in drug-eluting stents and biodegradable stents improving treatment outcomes and reducing complications [20]. - Market demand for PCI is expected to continue growing due to rising cardiovascular disease rates and increased public awareness of health [21]. - The industry faces intensified international competition, necessitating domestic companies to enhance innovation and expand into global markets [22]. Competitive Landscape - The PCI market in China is characterized by a mix of international giants like Medtronic and Abbott, and domestic companies such as Lepu Medical and Sino Medical, with the latter gaining market share through competitive pricing and innovative products [15][16]. - Companies like Weimai Medical and Yiju Medical are focusing on comprehensive solutions in interventional devices, with a strong emphasis on research and development [16][18].

Group 1 - The core index of the China Securities Internet Medical Theme Index (CS Internet Medical, 930720) opened lower but rose, closing at 2514.46 points with a trading volume of 6.017 billion yuan [1] - Over the past month, the CS Internet Medical Theme Index has decreased by 12.73%, increased by 15.90% over the past three months, and has risen by 5.70% year-to-date [1] - The index reflects the overall performance of representative companies providing hardware, software, or services for medical informationization and intelligence [1] Group 2 - The top ten weighted companies in the CS Internet Medical Theme Index are: Yifeng Pharmacy (6.65%), Daclin (6.44%), Laobaixing (6.21%), Wandong Medical (5.53%), Haier Biomedical (5.48%), Jiuzhoutong (5.44%), Yixintang (5.37%), Aier Eye Hospital (5.33%), Yuyue Medical (5.28%), and Lepu Medical (5.17%) [1] - The market share of the CS Internet Medical Theme Index holdings is 51.03% from the Shenzhen Stock Exchange and 48.97% from the Shanghai Stock Exchange [1] - The industry composition of the index holdings shows that 70.41% is in pharmaceuticals and healthcare, 25.78% in information technology, and 3.81% in communication services [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day after the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] Group 4 - Public funds tracking the CS Internet Medical Index include: Huatai-PineBridge China Securities Internet Medical A and Huatai-PineBridge China Securities Internet Medical C [3]

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 心未来 近日， 乐普（北京）医疗器械股份有限公司 （以下简称 " 乐普医疗 "）研发的用于对狭窄血管病变预处 理的" Vessridge® 冠脉棘突球囊扩张导管 "（国械注准 20253030679 ）正式获得国家药品监督管理局 （ NMPA ）的上市批准。 值得一提的是，这是国产 第4款 冠状动脉棘突球囊扩张导管。 棘突球囊 以普通球囊导管为基础，使用尼龙切割件，截面为 类三角形突起物 ，固定于球囊两端，在球囊 充盈扩张时，借助凸出于球囊表面的尼龙切割件将压力聚焦传递给血管内壁，达到切割血管内膜、扩张狭 窄血管的目的，从而更有效扩张狭窄血管，有助于减少血管不规则撕裂、降低夹层发生风险。 因此，棘突球囊的出现改善了复杂病变预处理的效果，能够提高手术即刻成功率及远期预后。 | 国家约品监管管理局 National Medical Products Administration | 2 言数据查询 首页 政务服务门户 | | --- | --- | | 目境 ...

Group 1 - The core viewpoint of the article highlights the significant decline in the stock price of Lepu Medical, which closed at 10.42 yuan, down 11.99%, with a rolling PE ratio of 27.71 times and a total market capitalization of 19.596 billion yuan [1] - The average PE ratio for the medical device industry is 43.33 times, with a median of 27.80 times, placing Lepu Medical at the 73rd position in the industry ranking [1] - As of September 30, 2024, Lepu Medical has 94,003 shareholders, an increase of 11,288 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Lepu Medical's main business includes medical devices, pharmaceuticals, medical services, and health management, with a strong focus on cardiovascular medical devices and leading technology in "interventional without implantation" [1] - The latest financial results for the third quarter of 2024 show that the company achieved an operating income of 4.785 billion yuan, a year-on-year decrease of 23.55%, and a net profit of 803 million yuan, down 40.70%, with a gross profit margin of 62.80% [1]

Core Viewpoint - The company Sichuan Ruijian Medical Technology Co., Ltd. (referred to as "Ruijian Medical") has submitted its initial public offering (IPO) application to the Beijing Stock Exchange, aiming to raise 482 million yuan, with significant connections to Lepu Medical [1][2]. Group 1: Company Overview - Ruijian Medical, established in August 2013, transitioned to a joint-stock system in 2016 and was listed on the New Third Board before being delisted in 2018. It was acquired by Hong Kong-listed company Puhua Heshun in 2021, which now controls 50.55% of Ruijian Medical [2]. - The actual controllers of Ruijian Medical are Pu Zhongjie and his mother-in-law Yufeng Liu, who is the ultimate controlling shareholder of Puhua Heshun [2]. Group 2: Financial Performance - Ruijian Medical's revenue from 2021 to the first nine months of 2024 was 2.61 billion yuan, 3.45 billion yuan, 4.11 billion yuan, and 3.42 billion yuan, respectively. The net profit for the same periods was 679.32 million yuan, 1.04 billion yuan, 1.46 billion yuan, and 926.27 million yuan [5][6]. - The company reported a revenue increase of 17.63% for 2024, reaching 4.83 billion yuan, but net profit and net profit excluding non-recurring items decreased by 12.63% and 5.88%, respectively, marking the first instance of revenue growth without profit growth in three years [5][6]. Group 3: Related Party Transactions - Ruijian Medical engaged in significant related party transactions, selling goods worth a total of 202 million yuan to related parties from 2021 to the first nine months of 2024, with Lepu Medical being a major customer [3][4]. - The company also had arrangements for salary payments with related parties, with amounts paid on behalf of employees totaling 116.96 million yuan, 131.09 million yuan, 148.55 million yuan, and 53 million yuan over the reporting periods [3][4]. Group 4: Market Dynamics - The implementation of volume-based procurement has led to a noticeable decline in the sales prices of Ruijian Medical's main products, with the average selling price of blood dialysis machines and blood perfusion devices dropping by over 10% from 2021 to the first nine months of 2024 [5][7]. - The sales prices for blood dialysis machines were 31.21 yuan, 30.83 yuan, 30.1 yuan, and 27.37 yuan, while blood perfusion devices were priced at 169.41 yuan, 164.14 yuan, 159.81 yuan, and 147.32 yuan during the same periods, reflecting a decline of approximately 12.3% and 13%, respectively [7]. Group 5: Future Plans - Ruijian Medical plans to issue up to 43 million new shares to raise a total of 482 million yuan, which will be allocated to projects related to high-value consumables for blood purification, new blood purification equipment, and the establishment of an innovative research center [7].

Group 1 - The company issued a total of 16.38 billion yuan in convertible bonds, with 16.38 million bonds at a face value of 100 yuan each [1][2] - The convertible bonds, named "Lepu Convertible Bond 2," began trading on April 19, 2021, and the conversion period started on October 8, 2021 [2][3] - As of March 31, 2025, the total number of remaining convertible bonds is 16,376,686, with a remaining amount of 1,637,668,600 yuan [3][4] Group 2 - The conversion price of the bonds was adjusted from 28.06 yuan per share to 27.92 yuan per share after the implementation of the 2024 semi-annual profit distribution plan [2][3] - During the conversion period from October 8, 2021, to March 31, 2025, the company saw a total of 10,766 shares converted from the bonds [3] - The total share capital of the company is 1,880,611,082 shares, with 85.93% being freely tradable shares [4]